Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
European Journal of Cancer (Oxford, England : 1990)|April 16, 2021
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysisFrancesco Schettini, Fabiola Giudici, Ottavia Bernocchi, et al.
Cancers|November 9, 2024
Predicting Additional Metastases in Axillary Lymph Node Dissection After Neoadjuvant Chemotherapy: Ratio of Positive/Total Sentinel NodesIsaac Cebrecos, Ines Torras, Helena Castillo, et al.
Critical Reviews in Oncology/Hematology|December 24, 2022
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectivesMarianna Sirico, Alessandra Virga, Benedetta Conte, et al.
The Oncologist|December 14, 2024
Identifying the best treatment choice for relapsing/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analysesFrancesco Schettini, Estela Pineda, Andrea Rocca, et al.
Menopause (New York, N.Y.)|December 30, 2017
Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective studyTiziana Pagano, Pasquale De Rosa, Roberta Vallone, et al.
The Oncologist|January 4, 2024
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II TrialFrancesco Schettini, Michela Palleschi, Francesca Mannozzi, et al.
JAMA Oncology|August 29, 2024
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-AnalysisGuillermo Villacampa, Victor Navarro, Alexios Matikas, et al.
Oncotarget|January 20, 2018
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysisCarmine De Angelis, Massimo Di Maio, Anna Crispo, et al.
Breast (Edinburgh, Scotland)|April 8, 2025
Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative reviewJavier Muñoz, Sabrina Nucera, Nuria Rubira Garcia, et al.
Breast (Edinburgh, Scotland)|October 2, 2023
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA studyMassimo Di Maio, Claudia Bighin, Francesco Schettini, et al.
Pageof 9